NFkB p65 antibody
|Applications||ICC/IF, IHC-P, WB, ChIP assay|
Not tested in other applications.
| ChIP assay||Assay-dependent dilution
|IHC (Formalin-fixed paraffin-embedded sections)||1:100-1:1000*
*Optimal dilutions/concentrations should be determined by the researcher.
|Predicted Target Size||60 kDa (note)
|Positive Controls||HeLa , A431 , HepG2 , human NFkB p65-transfected 293T|
(Please refer to the vial label for the specific concentration)|
|Purification||Purified by antigen-affinity chromatography.|
|Full Name||v-rel reticuloendotheliosis viral oncogene homolog A (avian)|
|Product Description||Rabbit Polyclonal antibody to NFkB p65 (v-rel reticuloendotheliosis viral oncogene homolog A (avian))|
|Background||NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA, or RELB (MIM 604758) to form the NFKB complex. The p50 (NFKB1)/p65 (RELA) heterodimer is the most abundant form of NFKB. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA, MIM 164008 or NFKBIB, MIM 604495), which inactivate NFKB by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by kinases (IKBKA, MIM 600664, or IKBKB, MIM 603258) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NFKB complex. Activated NFKB complex translocates into the nucleus and binds DNA at kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T; R is an A or G purine; and Y is a C or T pyrimidine).[supplied by OMIM]|
|Synonyms||MGC131774 antibody, NFKB3 antibody, p65 antibody, RELA antibody, nuclear factor NF-kappa-B p65 subunit antibody, transcription factor p65 antibody, NF-kappa-B p65delta3 antibody, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 antibody, v-rel reticuloendotheliosis viral oncogene homolog A (avian) antibody|
|Cellular Localization||Nucleus , Cytoplasm |
|Immunogen||Recombinant protein encompassing a sequence within the center region of human NFkB p65. The exact sequence is proprietary.|
|Species Reactivity||Human, Mouse|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Rat, Pig, Chimpanzee, Bovine|
|Predict Reactivity Note||Rat (99%), Pig (98%), Chimpanzee (99%), Bovine (98%)|